Skip to main content
SpringerLink
Log in
Book cover

TNF-alpha Inhibitors pp 83–99Cite as

Infliximab in dermatology, gastroenterology, and off-label use

  • Chapter

  • 979 Accesses

Part of the book series: Milestones in Drug Therapy ((MDT))

Conclusions

Many skin diseases involve derangement of the immune system, aberrant T cell function and excessive TNF-α production. Thus, it is understandable that infliximab ameliorates many skin diseases. In particular, those diseases that also manifest with arthritis — psoriasis, ankylosing spondylitis, rheumatoid arthritis, ulcerative colitis and Crohn’s disease — improve with treatment with infliximab. These diseases and Behcet’s disease, pyoderma gangrenosum and hidradentitis supprativa also are accompanied by excessive and aberrant neutrophils, whose function it would seem are normalized with infliximab treatment. The side effects of infliximab include inductions of inflammation (paradoxically), injection site reactions, lymphoma, autoantibodies, lupus and severe infections. These side effects and the substantial cost of infliximab remain barriers to its wide application in dermatology. Nevertheless, because its promise is so great, its indications and uses will undoubtedly expand in the future.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. http://www.rxlist.com/cgi/generic3/infliximab.htm (May 10, 2003)

    Google Scholar 

  2. http://www.fda.gov/cber/products/inflcen082498.htm (May 11, 2003)

    Google Scholar 

  3. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNFa monoclonal antibody cA2 binds recombinant transmembrane TNFa and activates immune effector functions. Cytokine 7: 251–259

    Article  PubMed  CAS  Google Scholar 

  4. Pittoni V, Bombardieri M, Spinelli FR, Scrivo R, Alessandri C, Conti F, Spadaro A, Valesini G (2002) Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 61: 723–725

    Article  PubMed  CAS  Google Scholar 

  5. Norgauer J, Dichmann S, Peters F, Mockenhaupt M, Schraufst tter I, Herouy Y (2003) Tumor necrosis factor alpha induces upregulation of CXC-chemokine receptor type II expression and magnifies the proliferative activity of CXC-chemokines in human melanocytes. Eur J Dermatol 13: 124–129

    PubMed  CAS  Google Scholar 

  6. Detkova Z, Kupcova V, Prikazska M, Turecky L, Weissova S, Jahnova E (2003) Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn’s disease. Physiol Res 52: 95–100

    PubMed  CAS  Google Scholar 

  7. Ringheanu M, Daum F, Markowitz J, Levine J, Katz S, Lin X, Silver J (2004) Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn’s disease. Inflamm Bowel Dis 10(6): 801–810

    Article  PubMed  Google Scholar 

  8. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR (2001) ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 120: 1347–1355

    Article  PubMed  CAS  Google Scholar 

  9. Kupcova V, Turecky L, Detkova Z, Prikazska M, Keleova A (2003) Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn’s disease. Physiol Res 52: 89–93

    PubMed  CAS  Google Scholar 

  10. Lamireau T, Cezard JP, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D et al., the French-Speaking Group for Pediatric Gastroenterology Nutrition (2004) Efficacy and tolerance of infliximab in children and adolescents with Crohn’s disease. Inflamm Bowel Dis 10: 745–750

    Article  PubMed  Google Scholar 

  11. Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117: 761–769

    Article  PubMed  CAS  Google Scholar 

  12. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317): 1541–1549

    Article  PubMed  CAS  Google Scholar 

  13. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350: 876–885

    Article  PubMed  CAS  Google Scholar 

  14. Bernstein CN (2002) Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 4: 513–516

    PubMed  Google Scholar 

  15. Katsanos KH, Christodoulou DK, Tsianos EV (2002) Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn’s disease patient. Am J Gastroenterol 97: 2155–2156

    Article  PubMed  Google Scholar 

  16. Martinez F, Nos P, Benlloch S, Ponce J (2001) Hidradenitis suppurativa and Crohn’s disease: response to treatment with infliximab. Inflamm Bowel Dis 7: 323–326

    Article  PubMed  CAS  Google Scholar 

  17. Mahadevan U, Sandborn WJ (2001) Infliximab for the treatment of orofacial Crohn’s disease. Inflamm Bowel Dis 7: 38–42

    PubMed  CAS  Google Scholar 

  18. Geyer AS, Anhalt GJ, Nousari HC (2000) Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn disease. Arch Dermatol 136: 459–460

    Article  PubMed  CAS  Google Scholar 

  19. Bens G, Laharie D, Beylot-Barry M, Vergier B, Noblesse I, Beylot C, Amouretti M (2003) Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn’s disease. Br J Dermatol 149: 181–184

    Article  PubMed  CAS  Google Scholar 

  20. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG (2001) Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 137: 930–933

    PubMed  CAS  Google Scholar 

  21. Oh CJ, Das KM, Gottlieb AB (2000) Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 42: 829–830

    Article  PubMed  CAS  Google Scholar 

  22. de Ridder L, Escher JC, Taminiau JA (2002) Infliximab therapy in children and adolescents with refractory Crohn’s disease in the Netherlands; experience with 23 patients. Ned Tijdschr Geneeskd 146: 1879–1883

    PubMed  Google Scholar 

  23. Miller AM, Elliott PR, Fink R, Connell W (2001) Rapid response of severe refractory metastatic Crohn’s disease to infliximab. J Gastroenterol Hepatol 16: 940–942

    Article  PubMed  CAS  Google Scholar 

  24. Basu A, Wexner SD (1999) Perianal Crohn’s disease. Curr Treat Options. Gastroenterol 5: 197–206

    Article  Google Scholar 

  25. Heller T, James SP, Drachenberg C, Hernandez C, Darwin PE (1999) Treatment of severe esophageal Crohn’s disease with infliximab. Inflamm Bowel Dis 5: 279–282

    Article  PubMed  CAS  Google Scholar 

  26. Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG (2003) Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 37:150–154

    Article  PubMed  CAS  Google Scholar 

  27. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B et al (2004) Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50: 3432–3443

    Article  PubMed  CAS  Google Scholar 

  28. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, St Clair EW, Keenan GF, van der Heijde D, Marsters PA et al (2004) Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50: 1051–1065

    Article  PubMed  CAS  Google Scholar 

  29. Baeten D, Kruithof E, Van den Bosch F, Van den Bossche N, Herssens A, Mielants H, De Keyser F, Veys EM (2003) Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 62: 829–834

    Article  PubMed  CAS  Google Scholar 

  30. Sieper J, Braun J (2001) New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy. Ann Rheum Dis 60Suppl 3: 58–61

    Google Scholar 

  31. http://www.spondylitis.org/News/NewsDefault.aspx?NewsID=176 (28 January 2004)

    Google Scholar 

  32. Marquart-Elbaz C, Lipsker D, Sibilia J, Faivre M, Grosshans E, Cribier B (2002) Painful edema of the feet revealing ankylosing spondylitis. Ann Dermatol Venereol 129: 889–891

    PubMed  CAS  Google Scholar 

  33. Almodovar R, Zarco P, Quiros FJ, Mazzucchelli R (2004) Infliximab treatment efficacy in lymphoedema associated with ankylosing spondylitis. Rheumatology (Oxford) 43: 1456

    Article  CAS  Google Scholar 

  34. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG (2003) Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 48:829–835

    Article  PubMed  Google Scholar 

  35. Schopf RE, Aust H, Knop J (2002) Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 46: 886–891

    Article  PubMed  Google Scholar 

  36. Amital H, Ingber A, Rubinow A (2003) Infliximab-induced remission of extensive plaque psoriasis. Isr Med Assoc J 5: 827–828

    PubMed  Google Scholar 

  37. Al-Salem IH (2003) Striking and rapid improvement of plaque psoriasis with infliximab. A report of two cases. Dermatology 207: 54–56

    Article  PubMed  CAS  Google Scholar 

  38. Gottlieb AB (2003) Infliximab for psoriasis. J Am Acad Dermatol 49(2 Suppl): S112–S117

    Article  PubMed  Google Scholar 

  39. Cather JC, Cather JC, Abramovits W (2003) Investigational therapies for psoriasis. J Am Acad Dermatol 49(2 Suppl): S133–S138

    Article  PubMed  Google Scholar 

  40. Cather JC, Cather JC, Abramovits W (2003) Investigational therapies for psoriasis. J Am Acad Dermatol 49(2 Suppl): S133–S138

    Article  PubMed  Google Scholar 

  41. Mang R, Stege H, Ruzicka T, Krutmann J (2002) Response of severe psoriasis to infliximab. Dermatology 204: 156–157

    Article  PubMed  CAS  Google Scholar 

  42. O’Quinn RP, Miller JL (2002) The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 138: 644–648

    Article  PubMed  Google Scholar 

  43. Chan JJ, Gebauer K (2003) Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Australas J Dermatol 44: 116–120

    Article  PubMed  Google Scholar 

  44. Gottlieb AB (2003) Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 12: 190–194

    Article  PubMed  CAS  Google Scholar 

  45. Wollina U, Konrad H (2002) Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol 16: 127–129

    Article  PubMed  CAS  Google Scholar 

  46. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842–1847

    Article  PubMed  CAS  Google Scholar 

  47. Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, Dooley LT, Fasanmade AA, Wagner CL (2003) Pharmacodynamic and pharmacokinetic response to antitumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48: 68–75

    Article  PubMed  Google Scholar 

  48. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E (2002) Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 22: 227–232

    Article  PubMed  CAS  Google Scholar 

  49. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47: 506–512

    Article  PubMed  CAS  Google Scholar 

  50. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, Bala M, Marano CW, Menter A (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51: 534–542

    Article  PubMed  Google Scholar 

  51. Newland MR, Weinstein A, Kerdel F (2002) Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 41: 449–452

    Article  PubMed  CAS  Google Scholar 

  52. Elewski BE (2002) Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 47: 796–797

    Article  PubMed  Google Scholar 

  53. Rongioletti F, Borenstein M, Kirsner R, Kerdel F (2003) Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatolog Treat 14: 222–225

    Article  PubMed  CAS  Google Scholar 

  54. Gaylis N (2003) Infliximab in the Treatment of an HIV Positive Patient with Reiter’s Syndrome. J Rheumatol 30: 407–411

    PubMed  Google Scholar 

  55. Lebwohl M (2003) Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 49(2 Suppl): S118–S124

    Article  PubMed  Google Scholar 

  56. Gach JE, Berth-Jones J (2003) Successful treatment of recalcitrant psoriasis with a combination of infliximab and hydroxyurea. J Dermatolog Treat 14: 226–228

    Article  PubMed  CAS  Google Scholar 

  57. Dalaker M, Bonesronning JH (2003) Treatment of severe psoriasis with anti-TNF-alpha-antibody and methotrexate. Tidsskr Nor Laegeforen 123: 1070–1071

    PubMed  Google Scholar 

  58. Kirby B, Marsland AM, Carmichael AJ, Griffiths CE (2001) Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 26: 27–29

    Article  PubMed  CAS  Google Scholar 

  59. Girolomoni G, Abeni D (2001) Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis. Arch Dermatol 137: 784–785

    PubMed  CAS  Google Scholar 

  60. Antoni C, Manger B (2002) Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 20: S122–S125

    PubMed  CAS  Google Scholar 

  61. Ogilvie AL, Antoni C, Dechant C, Manger B, Kalden JR, Schuler G, Luftl M (2001) Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 144: 587–589

    Article  PubMed  CAS  Google Scholar 

  62. Cassano N, Loconsole F, Amoruso A, Coviello C, Filieri M, Filotico R, Del Vecchio S, Vena GA (2004) Infliximab monotherapy for refractory psoriasis: preliminary results. Int J Immunopathol Pharmacol 17: 373–380

    PubMed  CAS  Google Scholar 

  63. Yazdani-Biuki B, Wohlfahrt K, Mulabecirovic A, Mueller T, Hermann J, Graninger WB, Brezinschek HP, Brezinschek RI (2004) Long term treatment of psoriatic arthritis with infliximab. Ann Rheum Dis 63: 1531–1532; author reply 1532

    PubMed  CAS  Google Scholar 

  64. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 64: 1150–1157

    Article  PubMed  CAS  Google Scholar 

  65. Ochsenkuhn T, Sackmann M, Goke B (2004) Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 16: 1167–1171

    Article  PubMed  Google Scholar 

  66. Shen EH, Das KM (2004) Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 38: 741–745

    Article  PubMed  CAS  Google Scholar 

  67. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M (2004) Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Eur Rev Med Pharmacol Sci 8: 235–237

    PubMed  CAS  Google Scholar 

  68. Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A (2004) Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 8: 231–233

    PubMed  CAS  Google Scholar 

  69. Serio RN (2003) Infliximab treatment of sarcoidosis. Ann Pharmacother 37: 577–581

    Article  PubMed  CAS  Google Scholar 

  70. Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE (2003) Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 48: 3542–3543

    Article  PubMed  Google Scholar 

  71. Morcos Z (2003) Refractory neurosarcoidosis responding to infliximab. Neurology 60: 1220–1221

    PubMed  Google Scholar 

  72. Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD (2002) Refractory neurosarcoidosis responding to infliximab. Neurology 59: 1660–1661

    PubMed  CAS  Google Scholar 

  73. Katz JM, Bruno MK, Winterkorn JM, Nealon N (2003) The pathogenesis and treatment of optic disc swelling in neurosarcoidosis: a unique therapeutic response to infliximab. Arch Neurol 60: 426–430

    Article  PubMed  Google Scholar 

  74. Mallbris L, Ljungberg A, Hedblad MA, Larsson P, Stahle-Backdahl M (2003) Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 48: 290–293

    Article  PubMed  Google Scholar 

  75. Meyerle JH, Shorr A (2003) The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2: 413–414

    PubMed  Google Scholar 

  76. Menon Y, Cucurull E, Reisin E, Espinoza LR (2004) Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci 328: 173–175

    Article  PubMed  Google Scholar 

  77. Thumfart J, Muller D, Rudolph B, Zimmering M, Querfeld U, Haffner D (2005) Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy. Am J Kidney Dis 45: 411–414

    Article  PubMed  Google Scholar 

  78. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD (2003) Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 139: 1540–1542

    Article  PubMed  Google Scholar 

  79. Lebwohl B, Sapadin AN (2003) Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 49(5 Suppl): S275–S276

    Article  PubMed  Google Scholar 

  80. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS (2003) Infliximab for hidradenitis suppurativa. Br J Dermatol 149(5): 1046–1049

    Article  PubMed  CAS  Google Scholar 

  81. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H (2002) Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 46: 1965–1968

    Article  PubMed  Google Scholar 

  82. Sfikakis PP (2002) Behcet’s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61Suppl 2: 51–53

    Google Scholar 

  83. Andreu M, Ramanoelina J, Fajnkuchen F, Mouthon L, Cohen P, Laroche L, Guillevin L (2002) Treatment of severe Behcet’s disease with anti-TNF-alpha: infliximab. A case report. Ann Med Interne (Paris) 153: 414–415

    Google Scholar 

  84. Saulsbury FT, Mann JA (2003) Treatment with infliximab for a child with Behcet’s disease. Arthritis Rheum 49: 599–600

    Article  PubMed  Google Scholar 

  85. Rozenbaum M, Rosner I, Portnoy E (2002) Remission of Behcet’s syndrome with TNFalpha blocking treatment. Ann Rheum Dis 61: 283–284

    Article  PubMed  CAS  Google Scholar 

  86. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet 358: 295–296

    Article  PubMed  CAS  Google Scholar 

  87. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA (2001) Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet’s disease: a case report. Gastroenterology 120: 995–999

    PubMed  CAS  Google Scholar 

  88. Kram MT, May LD, Goodman S, Molinas S (2003) Behcet’s ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 46: 118–121

    Article  PubMed  Google Scholar 

  89. Mussack T, Landauer N, Ladurner R, Schiemann U, Goetzberger M, Burchardi C, Folwaczny C, Heldwein W, Hallfeldt K (2003) Successful treatment of cervical esophageal perforation in Behcet’s disease with drainage operation and infliximab. Am J Gastroenterol 98: 703–704

    Article  PubMed  Google Scholar 

  90. Robertson LP, Hickling P (2001) Treatment of recalcitrant orogenital ulceration of Behcet’s syndrome with infliximab. Rheumatology (Oxford) 40: 473–474

    Article  CAS  Google Scholar 

  91. Estrach C, Mpofu S, Moots RJ (2002) Behcet’s syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 41: 1213–1214

    Article  CAS  Google Scholar 

  92. Unger L, Kayser M, Nusslein HG (2003) Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 62: 587–588

    Article  PubMed  CAS  Google Scholar 

  93. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR (2002) Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 61: 559

    Article  PubMed  CAS  Google Scholar 

  94. Airo P, Antonioli CM, Vianelli M, Toniati P (2002) Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford) 41: 347–349

    Article  CAS  Google Scholar 

  95. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, Guillevin L (2002) Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 41: 1126–1132

    Article  CAS  Google Scholar 

  96. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, Gause A (2002) Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford) 41: 1303–1307

    Article  CAS  Google Scholar 

  97. (2002) Induction of remission with infliximab in therapy-refractory Wegener’s granulomatosis — Follow-up of six patients. Dtsch Med Wochenschr 127: 2346

    Google Scholar 

  98. Lam precht P, Arbach O, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gause A, Gross WL (2002) Induction of remission with infliximab in therapy-refractory Wegener’s granulomatosis — Follow-up of six patients. Dtsch Med Wochenschr 127: 1876–1880

    Article  PubMed  CAS  Google Scholar 

  99. Hellmich B, Gross WL (2004) Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 5: 25–35

    Article  PubMed  CAS  Google Scholar 

  100. Ortiz-Santamaria V, Valls-Roc M, Sanmarti M, Olive A (2003) Anti-TNF treatment in secondary amyloidosis. Rheumatology (Oxford) 42: 1425–1426

    Article  CAS  Google Scholar 

  101. Rysava R, Merta M, Spicka I, Tesar V (2003) Current therapeutic possibilities in primary and secondary amyloidosis and our experience with 31 patients. Nephrol Dial Transplant 18Suppl 5: v38–40

    Article  PubMed  Google Scholar 

  102. Bruner RJ, Farag SS (2003) Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin Oncol 30: 509–519

    Article  PubMed  CAS  Google Scholar 

  103. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, Dietze L, Kronenwett R, Hunerliturkoglu A, Haas R (2001) Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 28: 47–49

    Article  PubMed  CAS  Google Scholar 

  104. Kharfan-Dabaja MA, Morgensztern D, Santos E, Goodman M, Fernandez HF (2003) Acute graft-versus-host disease (aGVHD) presenting with an acquired lupus anticoagulant. Bone Marrow Transplant 31: 129–131

    Article  PubMed  CAS  Google Scholar 

  105. Jacobsohn DA (2002) Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs 11: 1271–1280

    Article  PubMed  CAS  Google Scholar 

  106. Jacobsohn DA (2003) Emerging therapies for graft-versus-host disease. Expert Opin Emerg Drugs 8: 323–338

    Article  PubMed  CAS  Google Scholar 

  107. Carpenter PA, Sanders JE (2003) Steroid-refractory graft-versus-host disease: past, present and future. Pediatr Transplant 7(3 Suppl): 19–31

    Article  PubMed  Google Scholar 

  108. Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB (2003) Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 74: 119–124

    Article  PubMed  Google Scholar 

  109. Zaccagna A, Bertone A, Puiatti P, Picciotto F, Sprujevnik T, Santucci R, Rossini FP (2003) Antitumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn’s disease. Eur J Dermatol 13: 258–260

    PubMed  Google Scholar 

  110. Triantafillidis JK, Cheracakis P, Sklavaina M, Apostolopoulou K (2002) Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 37: 863–865

    PubMed  CAS  Google Scholar 

  111. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR (2003) Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 98: 1821–1826

    Article  PubMed  CAS  Google Scholar 

  112. Romero-Gomez M, Sanchez-Munoz D (2002) Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol 14: 907

    Article  PubMed  Google Scholar 

  113. Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM (2002) Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 37: 1108–1110

    Article  PubMed  CAS  Google Scholar 

  114. Batres LA, Mamula P, Baldassano RN (2002) Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr 34: 558–560

    Article  PubMed  Google Scholar 

  115. Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC (2003) Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 148: 813–816

    Article  PubMed  CAS  Google Scholar 

  116. El-Shabrawi Y, Hermann J (2002) Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109: 2342–2346

    Article  PubMed  Google Scholar 

  117. Mangge H, Heinzl B, Grubbauer HM, El-Shabrawi Y, Schauenstein K (2003) Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int 23: 258–261

    Article  PubMed  Google Scholar 

  118. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98: 1315–1324

    Article  PubMed  CAS  Google Scholar 

  119. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126: 19–31

    Article  PubMed  CAS  Google Scholar 

  120. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA (2000) Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 95: 3490–3497

    Article  PubMed  CAS  Google Scholar 

  121. McIlwain L, Carter JD, Bin-Sagheer S, Vasey FB, Nord J (2003) Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 36: 411–413

    Article  PubMed  CAS  Google Scholar 

  122. McIlwain L, Carter JD, Bin-Sagheer S, Vasey FB, Nord J (2003) Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 36: 411–413

    Article  PubMed  CAS  Google Scholar 

  123. McCain ME, Quinet RJ, Davis WE (2002) Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 41: 116–117

    Article  CAS  Google Scholar 

  124. Foroozan R, Buono LM, Sergott RC, Savino PJ (2002) Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 120: 985–987

    PubMed  Google Scholar 

  125. en Tusscher MP, Jacobs PJ, Busch MJ, de Graaf L, Diemont WL (2003) Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 326: 579

    Article  PubMed  Google Scholar 

  126. Kent PD, Davis JM 3rd, Davis MD, Matteson EL (2002) Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum 46: 2257–2258

    Article  PubMed  Google Scholar 

  127. Chan AT, Cleeve V, Daymond TJ (2002) Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 78: 47–48

    Article  PubMed  CAS  Google Scholar 

  128. (2003) Cutaneous ulceration with methotrexate. Prescrire Int 12: 59–60

    Google Scholar 

  129. Vanbiervliet G, Anty R, Schneider S, Arab K, Rampal P, Hebuterne X (2002) Sweet’s syndrome and erythema nodosum associated with Crohn’s disease treated by infliximab. Gastroenterol Clin Biol 26: 295–297

    PubMed  Google Scholar 

  130. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC (2002) Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 138: 1258–1259

    Article  PubMed  Google Scholar 

  131. Verea MM, Del Pozo J, Yebra-Pimentel MT, Porta A, Fonseca E (2004) Psoriasiform eruption induced by infliximab. Ann Pharmacother 38: 54–57

    Article  PubMed  Google Scholar 

  132. Lobel EZ, Korelitz BI, Warman JI (2003) Red man syndrome and infliximab. J Clin Gastroenterol 36: 186

    Article  PubMed  Google Scholar 

  133. Kiely PD, Johnson DM (2002) Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (Oxford) 41: 631–637

    Article  CAS  Google Scholar 

  134. Dumont-Berset M, Laffitte E, Gerber C, Dudler J, Panizzon RG (2004) Eczematous drug eruption after infliximab. Br J Dermatol 151: 1272–1273

    Article  PubMed  CAS  Google Scholar 

  135. Ramirez-Hernandez M, Marras C, Martinez-Escribano JA (2005) Infliximab-induced vitiligo. Dermatology 210: 79–80

    Article  PubMed  Google Scholar 

  136. Becker M, Rose CD, McIlvain-Simpson G (2004) Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. J Rheumatol 31: 2529–2530

    PubMed  Google Scholar 

  137. Wang LC, Medenica MM, Shea CR, Busbey S (2003) Infliximab-induced eczematid-like purpura of Doucas and Kapetenakis. J Am Acad Dermatol 49: 157–158

    Article  PubMed  Google Scholar 

  138. Wright RC (2003) Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 49: 160–161

    PubMed  Google Scholar 

  139. Katsanos KH, Christodoulou DK, Zioga A, Tsianos EV (2003) Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn’s disease: fallacy or coincidence? Inflamm Bowel Dis 9: 279

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center and Beth Israel Medical Center, New York, USA

    Noah Scheinfeld

Authors
  1. Noah Scheinfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY, 10025, USA

    Jeffrey M. Weinberg  & Robin Buchholz  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Scheinfeld, N. (2006). Infliximab in dermatology, gastroenterology, and off-label use. In: Weinberg, J.M., Buchholz, R. (eds) TNF-alpha Inhibitors. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7438-1_7

Download citation

Publish with us

Policies and ethics

Search

Navigation